From a diagnostic perspective, several non-invasive tools have been considered for endometrial cancer screening, including the qualitative assessment of the endometrium through a transvaginal ultrasound; measurement of blood-based serum markers, such as cancer antigen 125 (CA125); and Pap smear (7–9). This evidence concerns the gene MUC16 and endometrial cancer.